1- https://doi.org/10.1002/hep.32113
Reply.
- Dec 13, 2021
- Hepatology (Baltimore, Md.)
- Cynthia Wat +7 more
Abstract
Firstly, Dr Vaillant proposes RO7062931 should have exhibited greater HBsAg reductions, given the efficient RO7062931 liver uptake, rapid turnover of HBsAg, and rapid protein reductions observed with GalNAc-ASOs in other therapeutic indications. We find this reasoning unsatisfactory, primarily as there should be no expectations of similar potency for GalNAc-ASOs targeting different mRNA species.
- # Therapeutic Indications
- # mRNA Species
- # Efficient Uptake
- # Rapid Reductions
- # Liver Uptake
- # Similar Potency
- # Rapid Turnover
